Skip to main content
. 2017 Jun 14;8(4):851–861. doi: 10.1007/s13300-017-0279-y

Table 2.

Medications at baseline

Sulfonylureas (%) 0
Biguanides (%) 67
Alpha-GIs (%) 11
Glinides (%) 22
TZDs (%) 0
DPP4 inhibitors (%) 33
GLP1 receptor agonists (%) 0
ARBs (%) 33
Calcium channel blockers (%) 22
Statins (%) 33
Ezetimib (%) 11
Antiplatelet agents (%) 11

ARBs angiotensin receptor blockers, DPP4 dipeptidyl peptidase-4, GIs glycosidase inhibitors, GLP1 glucagon-like peptide-1, TZDs thiazolidinediones